Onc Nurse on Call

In this podcast, experts Emely Alfaro, DNP, RN, CNS, OCN, Marianne Davies, NP, DNP, MSN, APRN, BSN, and Stephanie McDonald, MSN, FNP-BC, AOCNP, discuss how to recognize, grade, and manage antibody-drug conjugate-associated toxicities.

In the final installment of an Oncology Nursing News special three-part podcast series, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, of Cleveland Clinic, and Sikander Ailawadhi, MD, of Mayo Clinic, analyzed the institutional integration, clinical workflows, and future care models for subcutaneous isatuximab-irfc (Sarclisa Escena). The discussion followed the U.S. Food and Drug Administration (FDA) approval of isatuximab-irfc administered via the CirCLIQ on-body delivery system (OBDS) across all approved multiple myeloma indications.

In this podcast, experts Benjamin P. Levy, MD; Laura Alder, MD; and Beth Sandy, MSN, CRNP, FAPO, discuss biomarker testing for actionable genomic alterations in non–small cell lung cancer, management of ALK-positive advanced disease, and adjuvant targeted therapy for resectable disease.

In the second episode of a special Oncology Nursing News podcast series, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, of Cleveland Clinic, and Sikander Ailawadhi, MD, of Mayo Clinic, discussed the structural innovations of on-body delivery systems in multiple myeloma care.

Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, of Cleveland Clinic, and Sikander Ailawadhi, MD, of Mayo Clinic, examine the transition toward automated on-body administration for multiple myeloma treatments. The discussion followed the U.S. Food and Drug Administration (FDA) approval of subcutaneous isatuximab-irfc (Sarclisa Escena) administered via the CirCLIQ on-body delivery system (OBDS) across all approved multiple myeloma indications.